Insulet's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Insulet's ROA in the third quarter of 2026?
Insulet Corporation achieved a return on average assets (ROA) of 13.44 % in its third quarter of 2026, this is above PODD's average return on assets of -5.48%.
Insulet Corporations assets during the 12 months ending in the third quarter of 2026 are valued at $3 billion

ROA has improved compared to 12.13% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 77 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 637, from total ROA ranking in the second quarter of 2026 at 963.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	12.74 %	-8.77 %	-15.07 %	-8.4 %	0.13 %
Y / Y Net Income Change	61.07 %	322.22 %	157.34 %	0.89 %	13.03 %
Net Income (TTM) in million	429	375	303	247	246
Return On Assets (TTM)	13.44 %	12.13 %	9.55 %	7.48 %	7.3 %
PODD's Total Ranking	# 637	# 963	# 840	# 877	# 433
Total Assets (TTM) in million	3,415	3,165	2,987	3,190	3,029
Seq. Total Assets Change	7.9 %	5.96 %	-6.37 %	5.32 %	-12.68 %
Seq. Net Income Change	48.53 %	4.28 %	-10.33 %	15.98 %	289.33 %

PODD's 5 Years Annual ROA >> Back to PODD Management Effectiveness >> Compare PODD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 19
Sector	# 78
Overall	# 480

Return On Assets Statistics
High	Average	Low
15.14 %	-5.48 %	-26.54 %
(Sep 30 2024)		(Sep 30 2012)

Financial Statements
Insulet's Assets	$ 3,415 million	PODD's Balance sheet
Insulet's Income	$ 141 million	Quarterly PODD's Income Statement
PODD's Income by Division		See PODD's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	3.33 %	19.3 %	14.97 %	9.87 %	9.39 %
Total Assets in million	3,190	3,088	2,588	2,251	2,049
Y / Y Net Income Change	-40.93 %	102.76 %	4384.78 %	-72.62 %	147.06 %
Net Income in million	247	418	206	5	17
Annual Return On Assets	7.75 %	13.55 %	7.97 %	0.2 %	0.82 %

PODD's 5 Years Annual ROA >> Back to PODD Management Effectiveness >> Compare PODD ROA to its Competitors

Comment on PODD's ROA in the fiscal year ending 2025

In the fiscal year 2025 Insulet's ROA decreased compared to previous year to 7.75 %, due to deterioration of net income -40.93 % to $247.10 million, from $418.30 million a year ago, as PODD's assets were $3,190.40 million.

More Return On Assets Ratios
PODD's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PODD's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PODD's Competitors
Subscribers only: Roa for Insulet's Suppliers
Subscribers only: Return On Assets for PODD's Customers

You may also want to know
PODD's Roi	PODD's Inventory Turnover Ratio	PODD's Growth Rates	PODD's Dividend Comparisons
	PODD's Profitability Ratios	PODD's Asset Turnover Ratio	PODD's Dividend Growth
PODD's Roe	PODD's Valuation Ratios	PODD's Financial Strength Ratios	PODD's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %

Date modified: 2026-11-06T12:56:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.